Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
Bruno Valentin SinnKarsten E WeberWolfgang Daniel SchmittPeter A FaschingWilliam Fraser SymmansJens-Uwe BlohmerThomas KarnEliane Tabea TaubeFrederick KlauschenFrederik MarméChristian SchemElmar StickelerBeyhan AtasevenJens HuoberGunter von MinckwitzBarbara SeligerCarsten DenkertSibylle LoiblPublished in: Breast cancer research : BCR (2019)
The study confirms the negative prognostic role of lymphocytes in HR+ breast cancer and points at a complex interaction between chemotherapy, endocrine treatment, and tumor immunogenicity. The results point at a subtype-specific and potentially treatment-specific role of tumor-immunological processes in breast cancer with different implications in triple-negative and hormone receptor-positive disease.